New Stock News | Di Zh Pharmaceutical (688192. SH) plans to list in Hong Kong. The China Securities Regulatory Commission requires additional clarification on the relationships between directors and senior executives.

The China Securities Regulatory Commission issued the "Supplementary Materials Requirements for Overseas Issuance and Listing Record (March 3, 2026 - March 13, 2026)". The International Department of the China Securities Regulatory Commission issued supplementary material requirements for 8 companies, including requesting Desheng Pharmaceutical to provide explanations on the relationships among directors and senior management. According to the disclosure by the Hong Kong Stock Exchange on January 23, Desheng (Jiangsu) Pharmaceutical Co., Ltd. (referred to as Desheng Pharmaceutical (688192.SH)) submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Goldman Sachs and Huatai International as their joint sponsors. The China Securities Regulatory Commission requested Desheng Pharmaceutical to provide explanations on the following matters and asked lawyers to verify and provide clear legal opinions: 1. Please explain the establishment and changes in share capital and shareholders since the establishment of the limited liability company according to the requirements of the "Regulatory Rules Application Guidelines - Overseas Issuance and Listing No. 2". 2. Please explain the relationships among directors and senior management according to the requirements of the "Regulatory Rules Application Guidelines - Overseas Issuance and Listing No. 2". 3. Whether the business scope and actual business of the company and its subsidiaries involve the development and application of human stem cells, gene diagnosis and treatment technology as specified in the "Special Management Measures for Foreign Investment Access (Negative List) (2024 Edition)", and provide clear evidence. According to the prospectus, Desheng Pharmaceutical is a commercial-stage biopharmaceutical company focusing on the treatment of tumors and blood system diseases. Their listed product, Surenege, is the only small molecule epidermal growth factor receptor tyrosine kinase inhibitor approved globally for the treatment of EGFR exon 20 insertion mutation-positive lung cancer. Established in 2017 as a spin-off from AstraZeneca, Desheng Pharmaceutical was formerly the AstraZeneca Global Oncology Translational Science Center - Asia Innovation Medicine and Early Development Center. The company has significant competitive advantages, including a strong research heritage, a scientific team with extensive experience and a track record in drug discovery and development, and insights into commercialization of innovative targeted drugs. Leveraging their professional expertise in disease mechanism research and advanced translational science and drug design platforms, Desheng Pharmaceutical has built a rich and competitive product pipeline. This includes two approved drugs (Surenege and Gorizev), a candidate drug in the registration clinical stage, three assets in the concept validation stage, and one asset in the early clinical stage.